[{"orgOrder":0,"company":"Edge Pharma","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Gastroenterology","graph2":"Approved","graph3":"Edge Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Edge Pharma \/ ANI Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Edge Pharma \/ ANI Pharmaceuticals"},{"orgOrder":0,"company":"Sonoran Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tobramycin","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sonoran Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sonoran Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sonoran Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Xellia Pharmaceuticals ApS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Xellia Pharmaceuticals ApS","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xellia Pharmaceuticals ApS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xellia Pharmaceuticals ApS \/ Not Applicable"},{"orgOrder":0,"company":"Savara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"inhalation powder","sponsorNew":"Savara \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"SER-287","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"HM Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Series B Financing","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Osteal Therapeutics \/ HM Capital","highestDevelopmentStatusID":"8","companyTruncated":"Osteal Therapeutics \/ HM Capital"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SER-155","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Vancomycin Hydrochloride","moa":"Cell wall synthesis","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Osteal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Osteal Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Vancomycin Hydrochloride","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Osteal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Osteal Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"SER-155","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"Asteroid Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Series C Financing","leadProduct":"Vancomycin Hydrochloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"","sponsorNew":"Osteal Therapeutics \/ Asteroid Partners","highestDevelopmentStatusID":"8","companyTruncated":"Osteal Therapeutics \/ Asteroid Partners"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Vedanta Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"VE202","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"PureTech Health \/ Vedanta Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Vedanta Biosciences"},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Vancomycin Hydrochloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Osteal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Osteal Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Series D Financing","leadProduct":"Vancomycin Hydrochloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Osteal Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Osteal Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"SER-155","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Seres Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Vancomycin Hydrochloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : SER-155 decreases the colonization and abundance of bacterial pathogens, and to enhance epithelial barrier integrity in the GI tract, decreasing the incidence of bloodstream infections.

                          Brand Name : SER-155

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 12, 2024

                          Lead Product(s) : SER-155,Vancomycin Hydrochloride

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The financing will advance the development of Osteal’s portfolio of therapies, including the submission of NDA and accelerated commercial launch of VT-X7 for treating PJI of the hip and knee.

                          Brand Name : VT-X7

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 05, 2024

                          Lead Product(s) : Vancomycin Hydrochloride,Tobramycin Sulfate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Johnson & Johnson

                          Deal Size : Undisclosed

                          Deal Type : Series D Financing

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : VT-X7 (vancomycin hydrochloride and tobramycin sulfate) for irrigation is a novel drug/device combination product which is delivers broad-spectrum antibiotics, directly to the joint space and surrounding tissue to treat periprosthetic joint infection (PJ...

                          Brand Name : VT-X7

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 05, 2023

                          Lead Product(s) : Vancomycin Hydrochloride,Tobramycin Sulfate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : VE202 is a first-in-class, orally administered, investigational live biotherapeutic product (LBP) consortium consisting of 16 strains of bacteria, which is investigated for the treatment of ulcerative colitis.

                          Brand Name : VE202

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 04, 2023

                          Lead Product(s) : VE202,Vancomycin Hydrochloride

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : Vedanta Biosciences

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The proceeds will support NDA submission and preparation for commercial launch of company's VT-X7, a novel drug/device combination product designed to deliver therapeutic concentrations of vancomycin hydrochloride and tobramycin, for periprosthetic joint...

                          Brand Name : VT-X7

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 21, 2023

                          Lead Product(s) : Vancomycin Hydrochloride,Tobramycin Sulfate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Asteroid Partners

                          Deal Size : $23.0 million

                          Deal Type : Series C Financing

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : SER-155 composition aims to decrease the colonization and abundance of bacterial pathogens, and to enhance epithelial barrier integrity in the GI tract to both reduce the likelihood of pathogen translocation and decrease the incidence of bloodstream infe...

                          Brand Name : SER-155

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          February 08, 2023

                          Lead Product(s) : SER-155,Vancomycin Hydrochloride

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : VT-X7 (vancomycin hydrochloride and tobramycin sulfate) for irrigation is a novel drug/device combination product which is delivers broad-spectrum antibiotics, directly to the joint space and surrounding tissue to treat periprosthetic joint infection (PJ...

                          Brand Name : VT-X7

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 07, 2023

                          Lead Product(s) : Vancomycin Hydrochloride,Tobramycin Sulfate

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : VT-X7, (Vancomycin Hydrochloride), a drug/device combination product that locally delivers, via irrigation, highly targeted antibiotic therapy to the hip or knee during an accelerated seven-day interstage period of a two-stage exchange arthroplasty.

                          Brand Name : VT-X7

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 04, 2022

                          Lead Product(s) : Vancomycin Hydrochloride,Tobramycin

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : SER-155, an oral consortium of cultivated bacteria, is a microbiome therapeutic candidate in clinical development. SER-155 is designed using microbiome biomarker data from human clinical data, human cell-based assays, and in vivo disease models.

                          Brand Name : SER-155

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          June 01, 2022

                          Lead Product(s) : SER-155,Vancomycin Hydrochloride

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The proceeds will enable Osteal to continue development of its integrated technologies, advance the clinical development of its lead candidate, VT-X7 for treatment of periprosthetic joint infection and fund new research programs.

                          Brand Name : VT-X7

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 08, 2022

                          Lead Product(s) : Vancomycin Hydrochloride,Tobramycin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : HM Capital

                          Deal Size : $30.0 million

                          Deal Type : Series B Financing

                          blank